Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

Yoko Goto; Ryo Ashida; Akira Nakamura; Satoshi Itasaka; Keiko Shibuya; Mami Akimoto; Nobutaka Mukumoto; Shigemi Matsumoto; Masashi Kanai; Hiroyoshi Isoda; Toshihiko Masui; Yuzo Kodama; Mitsuhiro Nakamura; Kyoichi Takaori; Takashi Mizowaki; Masahiro Hiraoka

doi:10.18632/oncotarget.25310

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

Yoko Goto _, Ryo Ashida, Akira Nakamura, Satoshi Itasaka, Keiko Shibuya, Mami Akimoto, Nobutaka Mukumoto, Shigemi Matsumoto, Masashi Kanai, Hiroyoshi Isoda, Toshihiko Masui, Yuzo Kodama, Mitsuhiro Nakamura, Kyoichi Takaori, Takashi Mizowaki and Masahiro Hiraoka

PDF | HTML | How to cite

Oncotarget. 2018; 9:23628-23635. https://doi.org/10.18632/oncotarget.25310

Metrics: PDF 1354 views | HTML 1769 views | ?

Abstract

Yoko Goto1, Ryo Ashida1, Akira Nakamura1, Satoshi Itasaka1, Keiko Shibuya2, Mami Akimoto1, Nobutaka Mukumoto1, Shigemi Matsumoto3, Masashi Kanai3, Hiroyoshi Isoda4, Toshihiko Masui5, Yuzo Kodama6, Mitsuhiro Nakamura1, Kyoichi Takaori5, Takashi Mizowaki1 and Masahiro Hiraoka1,7

1Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan

2Department of Radiation Oncology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan

3Department of Clinical Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

4Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

5Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

6Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

7Department of Radiation Oncology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan

Correspondence to:

Yoko Goto, email: [email protected]

Keywords: dynamic tumor tracking (DTT); intensity-modulated radiotherapy (IMRT); chemoradiotherapy; locally advanced pancreatic cancer; prognosis

Received: January 05, 2018 Accepted: April 14, 2018 Published: May 04, 2018

ABSTRACT

Objectives: We performed dynamic tumor-tracking IMRT (DTT-IMRT) in locally advanced pancreatic cancer (LAPC) patients using a gimbaled linac of Vero4DRT. The purpose of this study is to report the first clinical results.

Methods: From June 2013 to June 2015, eleven LAPC patients enrolled in this study and DTT-IMRT was successfully performed. The locoregional progression free survival (LRPFS), distant metastasis free survival (DMFS), overall survival (OS), hematologic and gastrointestinal (GI) toxicities were evaluated. Oncologic outcomes were estimated using Kaplan-Meier analysis, and toxicities using CTCAE v4.0.

Results: The median radiation dose was 48 Gy (range, 45-51) in 15 fractions. Concurrent chemoradiotherapy (CCRT) was performed using gemcitabine in 9 patients and S-1 in one, while one patient refused. With a median follow-up of 22.9 months, 1-year LRPFS, DMFS, and OS rates were 90.9%, 70.7%, and 100%, respectively. Median survival time was 23.6 months. Grade-3 leucopenia and neutropenia were observed in two (18%) and one patient (9%), respectively. Grade-2 acute GI toxicity occurred in 2 patients (18%) and late grade-3 in 1 patient (9%).

Conclusions: Preliminarily application of DTT-IMRT using a gimbaled linac on CCRT in LAPC patients resulted in excellent locoregional control and OS without severe toxicity.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25310

Publication Alerts

Research Papers:

Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac

Abstract